Merck Adds Phase II Oncology Candidate Via Acquisition Of Aton
Merck will have a Phase II oncologic drug candidate after completing the acquisition of privately held Aton Pharma
Merck will have a Phase II oncologic drug candidate after completing the acquisition of privately held Aton Pharma